 |
|
| DRUG DISCOVERY TODAY: DISEASE MECHANISMS
| |
| | |
|
|
Editors-in-Chief:
Toren Finkel, Charles Lowenstein
See editorial board for all editors information
Description
The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular
medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements
of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of
new drugs. This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.
Other titles in this series include:
Drug Discovery Today: Disease Models
Drug Discovery Today: Therapeutic Strategies
Drug Discovery Today: Technologies
Drug Discovery Today: Disease Mechanisms covers the analysis of the molecules
and pathways that fail or are subverted during the aetiology and pathogenesis of human disease. It focuses on what is actually known
or strongly predicted about the human disease process.
There will be 4 issues each year.
The Drug Discovery Today
reviews collection is only available online.
Ethics in Publishing: General Statement
The Editor(s) and Publisher of
this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount
to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors'
own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in
a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted
to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance
are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject
privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately
to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will
employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors
to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist
when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately
influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions
to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The
Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important
to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.
For
more information, please refer to:  http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest
Bibliographic & ordering information
ISSN: 1740-6765
Imprint: TRENDS
Commenced publication 2004
Subscriptions for the year 2009,
Volume 6,
4 issues
Institutional price: Order form
EUR 2,252 for European countries and Iran
JPY 299,100 for Japan
USD 2,532 for all countries except Europe, Japan and Iran
Conditions of sale & ordering procedures, and links to our regional sales offices.
Audience
Anyone working in life science, pharmaceutical or medical research with an interest in the applications directed to the prevention, diagnosis,
treatment or eradication of disease, and basic science researchers, medical researchers, clinicians, lecturers and students. This includes
employees in big and small pharma companies and medium to large biotech companies involved in either developing R&D technologies
or producing a large pipeline of innovative human therapies.
602/188
Last update: 8 Sep 2008
|
|
| |
| | |
|
|
| |
